PBU The Pension Fund of Early Childhood & Youth Educators Invests $9.08 Million in Zoetis Inc. $ZTS

PBU The Pension Fund of Early Childhood & Youth Educators bought a new position in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, HoldingsChannel reports. The fund bought 72,180 shares of the company’s stock, valued at approximately $9,082,000.

Other hedge funds have also bought and sold shares of the company. Nordea Investment Management AB raised its position in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares during the last quarter. Seilern Investment Management Ltd raised its position in Zoetis by 361.2% in the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after buying an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Zoetis by 134.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after buying an additional 935,432 shares during the last quarter. Pincus Capital Management LP purchased a new position in Zoetis in the 4th quarter worth about $2,109,000. Finally, Prudential PLC raised its position in Zoetis by 17.7% in the 3rd quarter. Prudential PLC now owns 197,852 shares of the company’s stock worth $28,950,000 after buying an additional 29,702 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis published the company’s 2025 Sustainability Report, highlighting progress in animal health and its next phase of sustainability goals. Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future
• Neutral Sentiment: The stock saw unusual call-option buying, suggesting some traders are positioning for a rebound despite the recent selloff. Zoetis (ZTS) rises as investors refocus on outlook and precision-animal-health expansion
• Neutral Sentiment: Zoetis’ valuation is being reassessed after its guidance cut and ongoing concerns about companion-animal demand and legal issues. A Look At Zoetis (ZTS) Valuation After Guidance Cut Legal Actions And Companion Animal Headwinds
• Negative Sentiment: Jim Cramer said he prefers Elanco over Zoetis, adding to negative investor sentiment around ZTS. Jim Cramer Recommends Elanco Over Zoetis
• Negative Sentiment: Multiple law firms announced or promoted class-action lawsuits against Zoetis, with allegations tied to alleged misleading statements, FDA safety warnings, and market-share erosion. ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: The company is also facing investor-notice deadlines and additional securities-fraud claims, keeping legal overhang front and center for shareholders. INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Analysts Set New Price Targets

A number of brokerages have weighed in on ZTS. Morgan Stanley reissued an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. UBS Group cut their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. cut their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average price target of $133.92.

Zoetis Trading Down 0.0%

Zoetis stock opened at $79.49 on Friday. The business has a 50-day simple moving average of $100.52 and a two-hundred day simple moving average of $115.54. The company has a market cap of $33.33 billion, a P/E ratio of 13.18, a P/E/G ratio of 1.24 and a beta of 0.75. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $171.52. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts predict that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s payout ratio is 35.16%.

Insider Activity at Zoetis

In related news, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.